First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors

Status:
RECRUITING

Trial end date:
2028-11-30

Target enrollment:

Participant gender:

This 2-part study will evaluate safety, tolerability, and clinical efficacy of DS-2243a as a treatment for participants with advanced solid tumors.

PHASE1

Daiichi Sankyo